It is usually mild to moderate and tends to improve over time as the body adjusts to the medication
It contributes 3-5% to the GLP-1 pharmaceutical ecosystem, primarily supporting users of semaglutide and tirzepatide
Glial cells to a very great extent define neuropathology, its progression and outcome: as long as glial defence prevails, the pathological process is resolved, whereas the failure of glial defence results in neuronal death and neurological deficits
We ask that patients enter the office unaccompanied
While not always separately quantified in clinical trial data, bloatingcharacterized by a sensation of abdominal fullness, distension, or tightnessis recognized as part of the broader spectrum of gastrointestinal side effects associated with GLP-1 receptor agonists
Vaishnava S, Yamamoto M, Severson KM et al (2011) The antibacterial lectin RegIII- promotes the spatial segregation of microbiota and host in the intestine